Focused on both endogenous growth and external expansion, Shenzhen Stock Exchange-listed Pacific Shuanglin Bio-pharmacy Co Ltd has achieved high-quality development during the 14th Five-Year Plan period (2021-25).

As a blood product maker, at the beginning of the 14th Five-Year Plan period, Pacific Shuanglin was in the second tier. It was then that the company formulated a "three-step" strategic development plan.

In the near future, it intends to achieve endogenous growth through a focus on internal tapping. In the mid-term, endogenous growth and outward expansion will be pursued simultaneously, with the promotion of mergers and acquisitions and integration to accelerate the company's expansion and development. In the long run, the company will seek to learn from the development direction of overseas blood product giants, follow international first-class standards, deepen its understanding of traditional blood products, actively explore non-blood related businesses, and strive to become a leading biotechnology enterprise.